

## INDEX

Sr. No.	TOPIC	Page No.
	<b>CONTENTS</b>	<b>I-IV</b>
	<b>LIST OF ABBREVIATIONS</b>	<b>V</b>
	<b>PREAMBLE</b>	<b>VI</b>
	<b>AIM AND OBJECTIVES</b>	<b>VIII</b>
<b>I</b>	<b><u>CHAPTER I. ANALYTICAL METHODS FOR MULTICOMPONENT SYSTEMS</u></b>	
	<b>Introduction</b>	<b>1</b>
<b>1.</b>	<b>Method 1. Development of HPLC and chemometric assisted spectrophotometric methods for the simultaneous determination of five active ingredients in cough and cold tablets and their application to dissolution study</b>	<b>11-53</b>
<b>1.1.</b>	Selection of formulation	<b>11</b>
<b>1.2.</b>	Drug profile	<b>11</b>
<b>1.3.</b>	Marketed formulation	<b>14</b>
<b>1.4.</b>	Literature review	<b>15</b>
<b>1.5.</b>	<b>Method 1A. HPLC method for the simultaneous determination of five active ingredients in cough and cold tablets : Application to dissolution study</b>	<b>15</b>
<b>1.5.1.</b>	Experimental	<b>15</b>
<b>1.5.2.</b>	Result and discussion	<b>19</b>
<b>1.6.</b>	<b>Method 1B. Chemometric assisted spectrophotometric methods for the simultaneous determination of five active ingredients in cough and cold tablets : Application to dissolution study</b>	<b>33</b>
<b>1.6.1.</b>	Experimental	<b>33</b>
<b>1.6.2.</b>	Result and discussion	<b>36</b>
<b>1.7.</b>	Statistical comparison of three methods	<b>50</b>
<b>1.8.</b>	Conclusion	<b>50</b>
<b>1.9.</b>	References	<b>51</b>

**II      CHAPTER II. QbD APPROACH FOR ANALYTICAL METHOD DEVELOPMENT**

<b>Introduction</b>	<b>54</b>
<b>2. Method 2. QBD approach for the development and optimisation of HPLC method for the simultaneous estimation of four component cream formulation: application to permeability study</b>	<b>60-93</b>
2.1. Selection of formulation	60
2.2. Drug profile	60
2.3. Marketed formulation	63
2.4. Literature review	63
2.5. Experimental	64
2.6. Result and discussion	68
2.7. Conclusion	90
2.8. References	90
<b>3. Method 3. Development of HPLC method for simultaneous estimation of Azelastine hydrochloride and Budesonide using QBD approach</b>	<b>94-133</b>
3.1. Selection of formulation	94
3.2. Drug profile	94
3.3. Marketed formulation	96
3.4. Literature review	96
3.5. <b>Plackett-Burman: Quality by Design approach for screening stage</b>	<b>97</b>
3.5.1. Experimental	97
3.5.2. Result and discussion	99
3.5.3. Conclusion	110
3.6. <b>Box-Behnken Design for HPLC method optimisation</b>	<b>111</b>
3.6.1. Experimental	111
3.6.2. Result and discussion	113
3.6.3. Conclusion	131
3.7. References	131

	<b>Method 4. Bioanalytical LCMS method development simultaneous estimation of Azelastine hydrochloride and Budesonide in rat plasma</b>	<b>134-176</b>
<b>4.1.</b>	Literature review	<b>134</b>
<b>4.2.</b>	Experimental	<b>134</b>
<b>4.3.</b>	Result and discussion	<b>145</b>
<b>4.4.</b>	Conclusion	<b>174</b>
<b>4.5.</b>	References	<b>174</b>
<b>III</b>	<b><u>CHAPTER III. STABILITY INDICATING ANALYTICAL METHODS (SIAM)</u></b>	
	<b>Introduction</b>	<b>177</b>
<b>5.</b>	<b>Method 5. Development of stability indicating analytical method for simultaneous estimation of Azelastine hydrochloride and Budesonide in bulk drug and laboratory mixture: Characterisation of major degradation products by LC-MS/MS technique</b>	<b>184-216</b>
<b>5.1.</b>	Literature review	<b>184</b>
<b>5.2.</b>	Experimental	<b>184</b>
<b>5.3.</b>	Result and discussion	<b>190</b>
<b>5.4.</b>	Conclusion	<b>214</b>
<b>5.5.</b>	References	<b>215</b>
<b>6.</b>	<b>Method 6. Development of stability indicating analytical method for Silodosin in bulk drug and formulation: Degradation kinetics and characterisation of major degradation products by LC-MS/MS technique</b>	<b>217-248</b>
<b>6.1.</b>	Selection of drug	<b>217</b>
<b>6.2.</b>	Drug profile	<b>217</b>
<b>6.3.</b>	Marketed formulation	<b>218</b>
<b>6.4.</b>	Literature review	<b>218</b>
<b>6.5.</b>	Experimental	<b>219</b>
<b>6.6..</b>	Result and discussion	<b>224</b>
<b>6.7.</b>	Conclusion	<b>246</b>
<b>6.8.</b>	References	<b>246</b>

<b>IV</b>	<b><u>CHAPTER IV. ANALYTICAL METHODS FOR QUALITY CONTROL OF DIFFERENT BRANDS</u></b>	
	<b>Introduction</b>	<b>249</b>
<b>7.</b>	<b>Method 7. Development of chemometric models to study the quality of Amoxicillin and Potassium clavulanate in commercial formulations by using NIR, Raman and FTIR techniques</b>	<b>255-299</b>
<b>7.1.</b>	Selection of formulation	<b>255</b>
<b>7.2.</b>	Drug profile	<b>256</b>
<b>7.3</b>	Literature review	<b>257</b>
<b>7.4.</b>	Experimental	<b>257</b>
<b>7.5.</b>	Construction of Models	<b>259</b>
<b>7.6.</b>	<b><u>Method 7A. Study of the quality of Amoxicillin brands</u></b>	<b>261</b>
<b>7.6.1.</b>	Marketed formulations and lab sample preparations	<b>261</b>
<b>7.6.2.</b>	Result and Discussion	<b>264</b>
<b>7.6.2.1</b>	NIR Method	<b>264</b>
<b>7.6.2.2</b>	Raman Method	<b>272</b>
<b>7.6.2.3</b>	FTIR Method	<b>276</b>
<b>7.6.3.</b>	Conclusion for AMX study	<b>281</b>
<b>7.7.</b>	<b><u>Method 7B. Study of the quality of Amoxicillin-Potassium clavulanate brands</u></b>	<b>282</b>
<b>7.7.1.</b>	Marketed formulations and lab sample preparations	<b>282</b>
<b>7.7.2.</b>	Result and Discussion	<b>285</b>
<b>7.7.2.1</b>	NIR Method	<b>285</b>
<b>7.7.2.2</b>	Raman Method	<b>289</b>
<b>7.7.2.3</b>	FTIR Method	<b>293</b>
<b>7.7.3.</b>	Conclusion for AMX-PC study	<b>297</b>
<b>7.8</b>	Conclusion	<b>297</b>
<b>7.9.</b>	References	<b>298</b>
	<b>SUMMARY</b>	<b>X</b>
	<b>PUBLICATIONS AND PRESENTATIONS</b>	<b>XIX</b>